Advisory service
Capital Allocation & Investment Analysis
Capital allocation analysis ranks competing investments — pipeline programs, licensing deals, manufacturing capacity, commercial launch spend — by the risk-adjusted value each one creates per dollar committed.
We help biotechnology and pharmaceutical leadership teams evaluate competing investment opportunities using objective financial analysis. Every recommendation is aligned with long-term strategic priorities and shareholder value creation.
Investment evaluation
Our analyses incorporate DCF, NPV, IRR, scenario modeling, and sensitivity analysis to compare investment alternatives and support confident capital allocation decisions.
Financial risk management
Every growing company faces financial risks, including market fluctuations, economic uncertainty, and unexpected operational challenges. Strategic financial planning involves identifying these risks and developing strategies to mitigate them. Companies can protect themselves by maintaining emergency reserves, diversifying revenue streams, and implementing strong financial controls.
Long-term financial planning
Sustainable growth requires a long-term perspective. Companies must look beyond immediate profits and consider how their financial decisions will impact the future. By aligning financial strategies with their overall business vision, companies can create a road map that supports continuous expansion and stability.
Live model
Try it on your own numbers
Adjusted NPV
$4.08B
Unadjusted
$5.54B
Implied share price
$9.34
Discount rate
10.0%
Swipe the table
| Code | Indication | Status | Launch | Peak sales | PoS | Adjusted NPV |
|---|---|---|---|---|---|---|
| LRA-045 | Major Depressive DisorderNeuropsychiatry | Filed | 2027 | $1,460M | 80% | $1.88B |
| LRA-201 | Post-Traumatic Stress DisorderNeuropsychiatry | Phase 3 | 2028 | $1,120M | 68% | $0.98B |
| LRA-114 | Generalized Anxiety DisorderNeuroscience | Phase 3 | 2029 | $730M | 58% | $0.45B |
| LRA-330 | Social Anxiety DisorderNeuroscience | Phase 2b | 2031 | $480M | 42% | $0.11B |
| LRA-078 | Chronic InsomniaSleep Medicine | Marketed | 2026 | $390M | 93% | $0.66B |
Long Range Advisory gave us a financial model our executive team actually used to make investment decisions. The analysis brought clarity to our capital allocation process and significantly improved our long-range planning discussions.
VP Finance
Mid-Size Biotechnology Company
Attributed as supplied · anonymous
Answers
Questions about capital allocation
How do you decide which program to fund first?
By risk-adjusted value created per dollar of capital required. A program with a smaller headline NPV can still rank first if it needs far less capital to reach its next value inflection point.
What happens when the budget will not cover every program?
That is the normal case, and it is the point of the analysis. The model shows what the portfolio is worth at each funding level, so leadership can choose deliberately rather than by seniority or momentum.